Health Care & Life Sciences » Pharmaceuticals | Hybio Pharmaceutical Co. Ltd.

Hybio Pharmaceutical Co. Ltd. | Income Statement

Fiscal year is January-December. All values CNY Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
300
415
757
843
1,224
1,243
Cost of Goods Sold (COGS) incl. D&A
46
72
169
188
220
215
Gross Income
254
343
588
654
1,004
1,028
SG&A Expense
120
158
236
301
624
820
EBIT
135
185
351
364
380
208
Unusual Expense
-
-
-
21
26
559
Non Operating Income/Expense
2
1
3
2
9
14
Interest Expense
-
12
34
41
26
48
Pretax Income
148
186
332
307
351
334
Income Tax
18
15
33
17
21
7
Equity in Affiliates
-
-
7
2
-
-
Consolidated Net Income
130
172
305
292
330
341
Net Income
130
172
305
292
330
341
Net Income After Extraordinaries
130
172
305
292
330
341
Net Income Available to Common
130
172
305
292
330
341
EPS (Basic)
0.16
0.22
0.34
0.32
0.36
0.37
Basic Shares Outstanding
800
800
890
918
918
917
EPS (Diluted)
0.16
0.21
0.34
0.32
0.35
0.37
Diluted Shares Outstanding
800
800
890
918
942
917
EBITDA
150
218
438
458
480
308
Other Operating Expense
-
-
-
-
11
-
Non-Operating Interest Income
8
10
3
3
14
39

About Hybio Pharmaceutical Co.

View Profile
Address
4/F, Hybio Biomedical Park Office
Shenzhen Guangdong 518057
China
Employees -
Website http://www.hybio.com.cn
Updated 07/08/2019
Hybio Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of polypeptide drugs. It offers Desmopressin acetate injection, Thymopentin, Somatostatin, Terlipressin, and Carbetocin for Injection. It focuses on building a digitalized chronic diseases management platform with the combination of drugs, medical instruments, and Internet.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.